Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Advice Statement

  • Home
  • Our Advice
  • PET-CT imaging in patients with anal cancer

Title

Output Type

Speciality

Published

Title

PET-CT imaging in patients with anal cancer

Output Type

Advice Statement

Speciality

Cancer, Digestive System

Published

7 April 2019

Recommendation for NHSScotland

In primary tumour staging in patients diagnosed with anal cancer, FDG PET-CT should be considered as an adjunct to clinical assessment and magnetic resonance imaging (MRI) or computed tomography (CT) imaging.

For radiotherapy treatment planning in patients with anal cancer, FDG PET-CT should be considered as an adjunct to clinical assessment and MRI or CT imaging.

It is not possible to provide advice on the use of FDG PET-CT for monitoring of treatment response in patients with anal cancer due to a lack of studies assessing this outcome.

There is uncertainty about the balance of costs and benefits of FDG PET-CT for anal cancer due to a lack of published cost effectiveness studies. Cost data for FDG PET-CT in Scotland should be collected in future to inform further assessments on this technology.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

We were asked to provide advice on the use of FDG PET-CT for the routine staging and monitoring of treatment response in patients with anal cancer

Why is this important?

The Scottish Clinical Imaging Network (SCIN) working group on PET-CT produce recommendations on the use of this technology in NHSScotland.  Our advice will be used to inform the SCIN use of PET-CT.

Referred by

The Scottish Clinical Imaging Network (SCIN) working group on PET-CT

 

Download icon
Download Advice
pdf (215 KB)
Download icon
Download Plain Language Summary
pdf (143 KB)
Download icon
Download Evidence Note
pdf (347 KB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 31 January 2022

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?